Search
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalBexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is ...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalBrigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPropiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalSparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalWhen levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebra...
Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalQuizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. A...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMacimorelin
go.drugbank.com/drugs/DB13074ApprovedMore specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels … Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMidecamycin
go.drugbank.com/drugs/DB13456InvestigationalMidecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...
Synonyms: Turimycin P3Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors